Last reviewed: July 3, 2026
Last updated: July 3, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has demonstrated significant weight loss effects in clinical trials, with participants losing up to 22% of body weight over 68 weeks. Not everyone qualifies for this medication, and determining eligibility requires careful medical evaluation beyond simple weight or BMI calculations. PlexusDx uses a comprehensive screening process to identify candidates who will benefit most from compounded semaglutide therapy.
Standard BMI and Weight Loss Eligibility Criteria
Traditional semaglutide eligibility typically begins with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. However, PlexusDx recognizes that BMI alone does not capture metabolic complexity or individual risk factors. A patient with a BMI of 26 who carries genetic markers for insulin resistance or GIPR pathway dysfunction may benefit from therapy, while another patient at BMI 35 might not be an ideal candidate based on their full health profile.
Weight-related conditions that may qualify patients at lower BMI thresholds include type 2 diabetes, hypertension, sleep apnea, fatty liver disease, and cardiovascular disease. PlexusDx evaluates these comorbidities as part of a holistic eligibility assessment. Patients with multiple weight-related health conditions may see faster metabolic improvements once semaglutide therapy begins, making them particularly strong candidates for treatment.
Medical History and Metabolic Health Assessment
Your medical history shapes semaglutide eligibility more than weight alone. PlexusDx screens for thyroid cancer, multiple endocrine neoplasia type 2, pancreatitis, gallbladder disease, and severe kidney or liver impairment, as these conditions warrant closer monitoring or may contraindicate therapy. A personal or family history of medullary thyroid cancer is a contraindication that permanently excludes patients from GLP-1 receptor agonist use due to animal study signals of C-cell hyperplasia.
Metabolic markers such as fasting glucose, HbA1c, insulin levels, and lipid panels inform whether semaglutide is appropriate for your metabolic state. Patients with prediabetes or insulin resistance often qualify because semaglutide improves both glucose control and insulin sensitivity independently of weight loss. PlexusDx requires basic bloodwork to confirm metabolic eligibility and establish baseline health markers before treatment begins.
Genetic Factors That Influence Semaglutide Responsiveness
Not all patients respond equally to semaglutide, and genetic variation plays a measurable role in treatment outcomes. PlexusDx's Precision Peptide Genetic Test identifies key variants—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—that predict how your body will respond to GLP-1 therapy. These variants affect receptor sensitivity, appetite regulation, and metabolic efficiency, meaning two patients with identical BMI and health profiles may experience different weight loss trajectories based on their genetic architecture.
Patients carrying loss-of-function variants in GLP1R may require higher doses or longer treatment periods to achieve target results, making them candidates for dose escalation. Conversely, patients with enhanced GIPR sensitivity may achieve significant weight loss on lower, more tolerable doses. By mapping 14 peptide pathways and 49 individual peptides, PlexusDx identifies whether your genetic profile predicts strong semaglutide responsiveness, weak responsiveness, or potential tolerance development—information that shapes both eligibility and treatment strategy.
Age, Pregnancy, and Special Population Considerations
PlexusDx does not prescribe semaglutide to patients under 18 years old, as safety and efficacy data remain limited in adolescents. Semaglutide is contraindicated in pregnancy and breastfeeding due to teratogenic signals in animal studies and the absence of human pregnancy data. Women of childbearing age must use effective contraception during treatment and for at least two months after the final injection, as semaglutide may remain in the system during this window.
Older adults may qualify for semaglutide therapy, though PlexusDx implements closer monitoring for dehydration, kidney function changes, and medication interactions. Patients with a history of pancreatitis, gallstones, or severe gastrointestinal disease warrant individualized risk-benefit assessment. Patients on insulin or certain diabetes medications may require dose adjustment once semaglutide begins, necessitating active coordination with their primary care physician during the first weeks of treatment.
How PlexusDx Determines Your Semaglutide Eligibility
PlexusDx begins with a detailed online health questionnaire that captures BMI, weight loss history, medical conditions, medications, family history, and lifestyle factors. This information is reviewed by a licensed healthcare provider who assesses safety and appropriateness. If initial screening is positive, PlexusDx orders or reviews recent bloodwork—typically fasting glucose, HbA1c, lipid panel, liver and kidney function tests, and thyroid markers—to confirm metabolic eligibility and rule out contraindications.
Once approved for treatment, patients may add the Precision Peptide Genetic Test ($99 add-on after the first month) to unlock personalized dosing strategy and compound selection. For example, a patient with strong GLP1R pathway signaling might start with compounded semaglutide injection at the entry price of $149/month, while a patient with multiple favorable genetic markers might be counseled on progression timelines. PlexusDx's pricing model ensures your dose may increase as your body adapts, but your price does not—removing financial barriers to dose optimization.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the minimum BMI to qualify for semaglutide at PlexusDx?
PlexusDx does not enforce a strict minimum BMI cutoff. Candidates with BMI 27+ and at least one weight-related condition (diabetes, hypertension, sleep apnea) typically qualify. Patients with BMI 25-27 may still be eligible if they have significant metabolic dysfunction or multiple health conditions. A PlexusDx provider reviews your full health picture to determine eligibility.
Do I need to have type 2 diabetes to qualify for semaglutide?
No. While semaglutide was originally approved for diabetes management, PlexusDx prescribes it for weight loss in patients without diabetes who meet BMI and health criteria. Many patients have prediabetes, insulin resistance, or metabolic syndrome without formal diabetes diagnosis, and these conditions support eligibility for therapy.
How much does semaglutide cost at PlexusDx, and what is covered?
Compounded semaglutide injection starts at $149 per month and remains $149/month regardless of dose level—your dose may go up, but your price won't. PlexusDx serves all 50 states without requiring insurance, and treatments are HSA/FSA eligible. There is no membership fee or enrollment cost.
Are there medical conditions that disqualify me from semaglutide?
Yes. A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 permanently excludes patients. Severe pancreatitis, severe kidney or liver disease, and current pregnancy also contraindicate therapy. PlexusDx screens for these during your initial consultation.
How does the Precision Peptide Genetic Test help determine if semaglutide is right for me?
The Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R that predict how your body responds to semaglutide specifically. Patients with genetic markers supporting strong GLP-1 pathway responsiveness typically achieve faster weight loss and better tolerability, while those with additional variants may benefit from a slower dose escalation or alternative compounded peptides like tirzepatide.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Insulin Resistance: Can Ozempic Play a Role in Your Health Journey?
Optimizing Your Ozempic Schedule: Can You Take It 5 Days Apart?